Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages

Leukemia and Lymphoma

Volumn 57, Issue 8, 2016, Pages 1839-1847

  Jakovic, Ljubomir R ^a,b   Mihaljevic, Biljana S ^a,b   Andjelic, Bosko M ^a,b   Bogdanovic, Andrija D ^a,b   Perunicic Jovanovic, Maja D ^a   Babic, Dragan D ^b   Bumbasirevic, Vladimir Z ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Advanced Hodgkin lymphoma; ALC AMC; IPS; TAM

Indexed keywords

BLEOMYCIN; CD68 ANTIGEN; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; VINBLASTINE; ANTINEOPLASTIC AGENT; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CELL RATIO; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; EVENT FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LYMPHOCYTE MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; ADJUVANT RADIOTHERAPY; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTE COUNT; MACROPHAGE; METABOLISM; MIDDLE AGED; MONOCYTE; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SALVAGE THERAPY; TUMOR MICROENVIRONMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHOCYTE COUNT; LYMPHOCYTES; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SALVAGE THERAPY; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84953335189     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1110745     Document Type: Article

References (36)

1. D.Hasenclever, V.Diehl A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998; 339: 1506–1514.
2. T.A.Lister, D.Crowther, S.B.Sutcliffe, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswold meeting. J Clin Oncol 1989; 7: 1630–1636.
3. M.Hutchings, A.Loft, M.Hansen, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52–59.
4. V.Diehl Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010; 7: 301–302.
5. J.S.Horning Risk, cure and complications in advanced Hodgkin disease. Hematology Am Soc Hematol Educ Program. 2007:197--203. [Review].
6. G.P.Schechter, L.M.Wahl, J.J.Oppenheim Suppressor monocytes in human disease: a review. Adv Exp Med Biol 1979; 121B: 283–298.
7. C.Steidl, T.Lee, S.P.Shah, et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl JMed 2010; 362: 875–885.
8. S.S.Dave, G.Wright, B.Tan, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169.
9. G.Lenz, G.Wright, S.S.Dave, et al. Lymphoma/leukemia molecular profiling project. Stromal gene signatures in large-B-cell lymphoma. N Engl J Med 2008; 359: 2313–2323.
10. L.Sehn Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006:295–302. [Review].
11. D.Canioni, G.Salles, N.Mounier, et al. High numbers of tumor associated macrophages have adverse prognostic value that can be circumvented by Rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440–446.
12. L.R.Jakovic, B.S.Mihaljevic, M.D.Perunicic Jovanovic, et al. Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma. Onkologie 2012; 35: 733–739.
13. L.R.Jakovic, B.S.Mihaljevic, M.D.Perunicic Jovanovic, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011; 52: 1913–1919.
14. B.Sanchez-Espiridion, A.M.Martin-Moreno, C.Montalban, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin’s lymphoma. Haematologica 2012; 97: 1080–1084.
15. Z.M.Li, J.J.Huang, Y.Xia, et al. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.
16. L.F.Porrata, K.Ristow, J.Colgan, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 2012; 97: 262–269.
17. D.A.Eichenauer, A.Engert, M.André, et al. ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25: iii70–iii75.
18. L.Specht Tumour burden as the main indicator of prognosis in Hodgkin’s disease. Eur J Cancer 1992; 28A: 1982–1985.
19. Clinical and Laboratory Standards Institute. Reference leukocyte differential count (proportional) and evaluation of instrument methods. Approved standard. CLSI document H20-A2. Wayne PA: CLSI; 2007.
20. S.H.Swerdlow, E.Campo, N.L.Harris,. WHO classification of tumors of hematopoetic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
21. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the 14th International Joint Conference on Artificial Intelligence 1995;2:1137–1143.
22. T.Tadmor Does monocyte count have prognostic significance in cancer? Leuk Res 2013; 37: 1193–1194.
23. P.Farinha, H.Masoudi, B.F.Skinnider, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169–2174.
24. G.X.Liu, X.Zhang, S.Li, et al. Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumour Biol 2013; 34: 2741–2746.
25. T.Tadmor, R.Fell, A.Polliack, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2013; 31: 325–331.
26. R.A.Wilcox, K.Ristow, T.M.Habermann, et al. The absolute monocyte count predicts overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 2012; 53: 575–580.
27. A.Bari, T.Tadmor, S.Sacchi, et al. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res 2013; 37: 619–623.
28. R.A.Wilcox, K.Ristow, T.M.Habermann, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011; 25: 1502–1509.
29. K.A.Von Hohenstaufen, A.Conconi, C.P.de Campos, et al. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol 2013; 162: 465–473.
30. M.A.Elliott, S.Verstovsek, D.Dingli, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31: 1503–1509.
31. Y.D.Tsai, C.P.Wang, C.Y.Chen, et al. Pretreatment circulating monocyte count associated with poor prognosis in patients with oral cavity head and neck cancer. Head Neck 2014; 36: 947–953.
32. J.J.Sáenz, J.J.Izura, A.Manrique, et al. Early prognosis in severe sepsis via analyzing the monocyte immunophenotype. Intensive Care Med 2001; 27: 970–977.
33. W.K.Young, J.K.Hyo, P.Chansik, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. The Oncologist 2012; 17: 871–880.
34. L.F.Porrata, K.M.Ristow, T.M.Habermann,. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer J 2013; 3: e110. DOI: 10.1038/bcj.2013.8.
35. L.F.Porrata, D.J.Inwards, S.M.Ansell,. Day 100 peripheral blood absolute lymphocyte/monocyte ratio and survival in classical Hodgkin’s lymphoma postautologous peripheral blood hematopoietic stem cell transplantation. Bone Marrow Res 2013; 2013: 658371.
36. A.Romano, C.Vetro, D.Donnarumma, et al. Early interim 2-(1) fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to peripheral blood. Haematologica 2012; 97: e21–e23.